Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 1/20 | 0.42 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 5/20 | 0.38 |
| ▸ | CA12 | O43570 | 4/20 | 0.38 |
| ▸ | CA9 | Q16790 | 4/20 | 0.38 |
| ▸ | CA1 | P00915 | 3/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | LGALS8 | O00214 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.33 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5318200 | 1.00 | SLC2A1 (0.42) | SLC2A1LGALS3CA2CA12CA9 | |
| SCHEMBL741519 | 1.00 | SLC2A1 (0.42) | SLC2A1LGALS3CA2CA12CA9 | |
| SCHEMBL1116562 | 0.91 | LGALS3 (0.39) | SLC2A1LGALS3CA2CA12CA9 | |
| SCHEMBL1116558 | 0.91 | LGALS3 (0.39) | SLC2A1LGALS3CA2CA12CA9 | |
| SCHEMBL4747690 | 0.91 | LGALS3 (0.39) | SLC2A1LGALS3CA2CA12CA9 | |
| SCHEMBL8201748 | 0.91 | LGALS3 (0.39) | SLC2A1LGALS3CA2CA12CA9 | |
| SCHEMBL3653142 | 0.87 | CA2 (0.40) | SLC2A1LGALS3CA2CA12CA9 | |
| SCHEMBL8003273 | 0.87 | CA2 (0.40) | SLC2A1LGALS3CA2CA12CA9 | |
| SCHEMBL1116556 | 0.87 | CA2 (0.40) | SLC2A1LGALS3CA2CA12CA9 | |
| SCHEMBL22121795 | 0.87 | CA2 (0.40) | SLC2A1LGALS3CA2CA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0929562-A1 | ACID-FUNCTIONALIZED SACCHARIDES AS POLYVALENT ANTI-INFECTIVES | GELTEX PHARMACEUTICALS, INC. (US) | 1999-07-21 | — | — | EP | claimed |
| WO-1998012203-A1 | ACID-FUNCTIONALIZED SACCHARIDES AS POLYVALENT ANTI-INFECTIVES | GELTEX PHARMACEUTICALS, INC. (US) | 1998-03-26 | — | — | WO | claimed |
| US-5700458-A | Acid-functionalized saccharides as polyvalent anti-infectives | GELTEX PHARMACEUTICALS INC. (US) | 1997-12-23 | — | — | US | claimed |
| US-20250313646-A1 | GLYCOENGINEERED ANTIBODIES | AUGMENT BIOLOGICS, INC. | 2025-10-09 | — | — | US | disclosed |
| US-20250273287-A1 | GLYCOSYLATION ENGINEERING | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2025-08-28 | — | — | US | disclosed |
| EP-4511401-A2 | GLYCOENGINEERED ANTIBODIES | Augment Biologics, Inc. (US) | 2025-02-26 | — | — | EP | disclosed |
| US-20240366853-A1 | METHOD FOR MODULATING ENDOTHELIAL GLYCOCALYX STRUCTURE | EXTHERA MEDICAL CORPORATION (US) | 2024-11-07 | — | — | US | disclosed |
| US-20240355424-A1 | CLINICAL DIAGNOSTICS USING GLYCANS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2024-10-24 | — | — | US | disclosed |
| US-12090261-B2 | Method for modulating endothelial glycocalyx structure | EXTHERA MEDICAL CORPORATION (US) | 2024-09-17 | — | — | US | disclosed |
| WO-2023205642-A2 | GLYCOSYLATION ENGINEERING | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-10-26 | — | — | WO | disclosed |
| WO-2023205659-A2 | GLYCOENGINEERED ANTIBODIES | AUGMENT BIOLOGICS, INC. (US) | 2023-10-26 | — | — | WO | disclosed |
| US-6235720-B1 | DRUG; MICROBIOCIDE, VIRICIDE, BACTERICIDE, ANTIPROTOZOA AGENT | GELTEX PHARMACEUTICALS, INC. | 2001-05-22 | — | — | US | disclosed |
| WO-1999028747-A9 | METHODS FOR SCREENING THERAPEUTICALLY EFFECTIVE AGENTS | WAYNE JOHN CANCER INST (US) | 1999-09-10 | — | — | WO | disclosed |
| US-5939537-A | Acid-functionalized saccharide monomers | GELTEX PHARMACEUTICALS INC. (US) | 1999-08-17 | — | — | US | disclosed |
| WO-1999028747-A1 | METHODS FOR SCREENING THERAPEUTICALLY EFFECTIVE AGENTS | JOHN WAYNE CANCER INSTITUTE (US) | 1999-06-10 | — | — | WO | disclosed |
| US-5821312-A | Acid-functionalized saccharides as polyvalent anti-infectives | GELTEX PHARMACEUTICALS, INC. (US) | 1998-10-13 | — | — | US | disclosed |
| US-5700458-A | Acid-functionalized saccharides as polyvalent anti-infectives | GELTEX PHARMACEUTICALS INC. (US) | 1997-12-23 | — | — | US | disclosed |
| US-5658880-A | PREVENT SELECTIN BINDING; ANTIINFLAMMATORY, ANTICANCER AGENTS; AIDS THERAPY | GLYCOMED INCORPORATED (US) | 1997-08-19 | — | — | US | disclosed |
| US-5653970-A | CLEANING COMPOUNDS; COSMETICS | LEVER BROTHERS COMPANY, DIVISION OF CONOPCO, INC. (US) | 1997-08-05 | — | — | US | disclosed |
| WO-1996005209-A9 | SIALIC ACID/FUCOSE BASED MEDICAMENTS | — | 1996-04-11 | — | — | WO | disclosed |